European Journal of Cancer
Volume 45, Issue 9 , Pages 1649-1653 , June 2009

Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?

Received 8 December 2008 ,Revised 12 January 2009 ,Accepted 15 January 2009.

References 

  1. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol. 2007;63:843–849
  2. In:  Smith A editors. IARC monographs on the evaluation of carcinogenic risks to humans. Hormonal contraception and post-menopausal hormonal therapy. vol. 72:Lyon: IARC; 1999;
  3. Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer. 2008;44:2344–2349
  4. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med. 2007;356:1670–1674
  5. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res. 2007;9(3):R28
  6. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152–1161
  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women’s Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  8. General Practice Research database (GPRD) <http://www.gprd.com/home/>.
  9. Beral V. Million women study collaborators breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362:419–427
  10. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–1389
  11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997;350:1047–1059
  12. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. WHI Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomised trial. JAMA. 2003;289:3243–3253
  13. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007;25:3437–3439
  14. Paci E, Duffy S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res. 2005;7:266–270
  15. Seppanen J, Heinavaara S, Anttila A, Sarkeala T, Virkkunen H, Hakulinen T. Effects of different phases of an invitational screening program on breast cancer incidence. Int J Cancer. 2006;119:920–924
  16. Department of Health. Health care statistics. Breast cancer screening programme, England. <http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalhealthcare/DH_4086491>; 2007b.
  17. Blanks RG, Bennett RL, Patnick J, et al. The effect of changing from one to two views at incident (subsequent) screens in the NHS breast screening programme in England: impact on cancer detection and recall rates. Clin Radiol. 2005;60:674–680
  18. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008;188:641–644
  19. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008;107:427–430
  20. Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van Leeuwen FE. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol. 2007;25(31):5038–5039

PII: S0959-8049(09)00023-9

doi: 10.1016/j.ejca.2009.01.016

European Journal of Cancer
Volume 45, Issue 9 , Pages 1649-1653 , June 2009

Article Tools

* Image Usage & Resolution